Navigation Links
Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
Date:8/10/2011

iscovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031 and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031 and LX1033. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031 and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
3. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
4. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
5. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
7. Lexicon to Provide First Quarter 2011 Financial Results
8. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
9. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
11. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com ... report is available in its catalogue: ... Application and Approval of Imported Medical ... (2014 Edition) ... Now, Chinese regulations on medical devices ...
(Date:8/27/2014)... Aug. 27, 2014  CVS Caremark (NYSE: ... new clinical affiliation with MedStar Health, a leading health ... and the Washington, DC ... health care services for patients. Through this clinical affiliation, ... clinical support, medication counseling, chronic disease monitoring and wellness ...
(Date:8/27/2014)... THOUSAND OAKS, Calif. , Aug. 27, 2014 /PRNewswire/ ... the U.S. Food and Drug Administration (FDA) has granted ... chronic heart failure (HF). Ivabradine is an oral drug ... ("funny" current) in the sinoatrial node, the body,s cardiac ... rate without negative effects on myocardial contractility or ventricular ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7
... April 1 , - Trial Results Expected Mid-2008, ... on vascular diseases, eye diseases and cancer, today announces ... MIVI III trial in the,United States. This study is ... vitrectomy (MIVI III - Microplasmin for Vitreous,Injection)., A ...
... As temperatures grow warmer,the American Heartworm Society (AHS) wants ... the heartworm disease risk it carries for pets., ... warmer months,when the mosquito population increases, the AHS recommends ... prevention every,month, forgetful pet owners will have their pets ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 2ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 3ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 4Mosquito Season Approaching: American Heartworm Society Reminds Pet Owners of Risk 2
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The need for ... over the past few years. The new location - 4700 ... higher quality and larger office space than TLC had in ... , “We are pleased about our new location because it ... our suite will be double in size compared to the ...
(Date:8/27/2014)... Author and orthopedic surgeon William H. Simon’s ... thrilling adventures of sharp and witty Dr. Ham ... up for a new marketing push in the second ... , “Prescription: Murder” follows the adventures of Ham Marks, ... attempts and thwarting criminals. In the first novella, “Over ...
(Date:8/27/2014)... an innovative company that provides many kinds of top quality ... are now offered on its website. In addition, the firm ... that place an order for its newly released items can ... , The company’s senior spokesman was excited to talk ... and old customers can buy cheap bamboo panels on our ...
(Date:8/27/2014)... National Resident Matching Program International (NRMPI) ... Education in Europe (AMEE) Conference being held at the ... September 3, 2014. As an exhibitor, NRMPI will ... share the benefits of its matching services, and discuss ... countries throughout the world. , “Exhibiting at ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:William H. Simon Launches New Marketing Campaign for Book 2Health News:BambooIndustry.com: Cheap Bamboo Panels for Clients Worldwide Offered Online 2Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2
... CRANSTON, R.I., Nov. 27 A new, ... manufacturers (OEMs) on choosing the,right electronics manufacturing ... available free to download at, http://www.federalelec.com/medicalpaper ., ... need for consistent quality and,conformance to product ...
... 27, 2007, 4:00 p.m. E.S.T. - Positron emission tomography ... need for more accurate staging of lung cancer and ... published online today in Journal of National Cancer Institute. ... Cancer Disease Site Group of Cancer Care Ontarios Program ...
... Nov. 27 A new study that shows young ... for men has leveled off offers,strong evidence that preventive ... war on cardiovascular disease, said Christopher T. Fey, the,chairman ... released study published in Journal of the American College ...
... therapies, experts say , , TUESDAY, Nov. 27 (HealthDay News) ... doctors predict which postmenopausal women are likely to sustain ... algorithm includes 11 different factors -- such as age ... of different ethnic backgrounds. , "Knowing the 5-year ...
... Risk Elevated in Male BRCA Mutation Carriers , Men with ... of breast cancer than the general population. , Male breast cancer ... the U.S., and it is most common in men with a ... who carry mutations in the BRCA2 gene have a greater risk ...
... R.I. [Brown University] Heavy smoking and drinking are ... human papillomavirus type 16 (HPV16), a common strain of ... for head and neck cancer, which affects about 500,000 ... however, shows that alcohol and tobacco use doesnt further ...
Cached Medicine News:Health News:White Paper Details How to Choose the Right EMS Provider for Medical Products Outsourcing 2Health News:PET imaging significantly enhances standard imaging in lung cancer staging 2Health News:US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care 2Health News:US Preventive Medicine(R) Says Study on Heart Disease-related Deaths Demonstrates Need for Preventive Medical Care 3Health News:Criteria Predict Women's 5-Year Risk for Fracture 2Health News:Other Highlights in the Nov. 27 JNCI 2Health News:Other Highlights in the Nov. 27 JNCI 3Health News:Other Highlights in the Nov. 27 JNCI 4Health News:Drinking and smoking don't boost HPV-related cancer risk 2
... an all-in-one drape made of 3M Steri-Drape ... pouch with filter and exit port. It ... inches (164cm) TUR Drape, Absorbent Prevention Fabric, ... cot, Fluid collection pouch with filter and ...
... Both the Penilab IV and the Penilab V have ... Model 1060 is similar to the Model 1061 ... can one be added later. The Penilab V ... all of the accessories you'll need to get started. ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... Integra II SP MRI-Compatible Anesthesia System is perfect ... more than one type of anesthetic agent. ... and due to its wider stance, has a ... ventilator bellows assembly is utilized in both the ...
Medicine Products: